These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. [Indications for stimulation procedures in neoplasms]. Szreder W Przegl Lek; 1965; 21(9):532-3. PubMed ID: 5854908 [No Abstract] [Full Text] [Related]
63. Comparison of four radiofrequency ablation systems at two target volumes in an ex vivo bovine liver model. Rathke H; Hamm B; Güttler F; Rathke J; Rump J; Teichgräber U; de Bucourt M Diagn Interv Radiol; 2014; 20(3):251-8. PubMed ID: 24509185 [TBL] [Abstract][Full Text] [Related]
71. Local ablative therapies in HCC: percutaneous ethanol injection and radiofrequency ablation. Mahnken AH; Bruners P; Günther RW Dig Dis; 2009; 27(2):148-56. PubMed ID: 19546553 [TBL] [Abstract][Full Text] [Related]
72. Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation. Hori T; Nagata K; Hasuike S; Onaga M; Motoda M; Moriuchi A; Iwakiri H; Uto H; Kato J; Ido A; Hayashi K; Tsubouchi H J Gastroenterol; 2003; 38(10):977-81. PubMed ID: 14614605 [TBL] [Abstract][Full Text] [Related]
73. [Randomized clinical trial of percutaneous radiofrequency ablation plus absolute ethanol injection compared with radiofrequency ablation alone for small hepatocellular carcinoma]. Chen MS; Zhang YJ; Li JQ; Liang HH; Zhang YQ; Zheng Y Zhonghua Zhong Liu Za Zhi; 2005 Oct; 27(10):623-5. PubMed ID: 16438875 [TBL] [Abstract][Full Text] [Related]